Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Neoadjuvant anastrozole alone or with gefitinib in early breast cancer


ABSTRACT: Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks. 96 samples

ORGANISM(S): Homo sapiens

SUBMITTER: Thomas Jensen 

PROVIDER: E-GEOD-48906 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2014-01-08 | GSE48906 | GEO
2011-12-20 | GSE33658 | GEO
2011-12-08 | E-GEOD-12665 | biostudies-arrayexpress
2016-07-15 | E-GEOD-71063 | biostudies-arrayexpress
2016-07-15 | E-GEOD-71064 | biostudies-arrayexpress
2023-07-31 | PXD042759 | Pride
2013-04-01 | E-GEOD-45468 | biostudies-arrayexpress
2022-09-08 | GSE207022 | GEO
2023-05-16 | GSE185773 | GEO
2023-09-01 | E-MTAB-12837 | biostudies-arrayexpress